Navigating the Pre-Approval and Approval Process for Drugs and Biologics

Banner Witcoff’s Mercedes Meyer, Ph.D., will present at the American Conference Institute’s (ACI)FDA Bootcamp on Wednesday, March 19.

Mercedes and her co-presenter will discuss the pre-approval and approval process for drugs and biologics. The presentation will cover:

The Drug Review Process

  • Reviewing the fundamentals of applications; from submission, through filing and beyond
  • Making sense of PDUFA Goals, fast track, break through status, and other process enhancements
  • Use of administrative appeals

Rx Drugs (Small Molecules)

  • Understanding the difference between “new drugs” and other drugs
  • Examining the research, development, and approval process for new drugs
  • Dissecting the investigational new drug application (IND) vs. the new drug application (NDA)

Biological Products (Large Molecules)

  • What are biological products in relation to traditional drugs?
  • Deciphering the biologics license application (BLA)
  • How do the research, development, and approval process for biological products differ from the process for new drugs?
  • Exploring key similarities and differences between the drug and biological product schemes

NDAs and BLAs

  • Differentiating between 505(b)(1)s, 505(b)(2)s, and BLAs
  • Identifying applications for fixed-dose combination drugs
  • Distinguishing complex molecules regulated through NDAs from from small molecules
  • Examining standards for approvals
  • REMS

More information about this event can be found by clicking here.

Contact Banner Witcoff Share on LinkedIn View this page as a pdf Share on Twitter Email this page Print this page